Northwest Biotherapeutics, Inc. (NWBO)

0.23
OTC Markets
Prev Close 0.23
Day Low/High 0.23 / 0.24
52 Wk Low/High 0.18 / 0.35
Exchange OTC Markets
Shares Outstanding 578.51B
Market Cap 135.95M
Div & Yield N.A. (N.A)
Why Northwest Bio's DCVax Brain Tumor Vaccine Will Blow Up Just Like ImmunoCellular's ICT-107

Why Northwest Bio's DCVax Brain Tumor Vaccine Will Blow Up Just Like ImmunoCellular's ICT-107

Dendritic cancer vaccines are too weak to be effective.

Interesting NWBO Put And Call Options For July 2014

Interesting NWBO Put And Call Options For July 2014

Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the July 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Why Seeking Alpha's Larry Smith Is Wrong Again About Northwest Bio.

Why Seeking Alpha's Larry Smith Is Wrong Again About Northwest Bio.

A critique of Smith's critique of my bearish view of Northwest Bio and its brain tumor therapy.

Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma

Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

(Graphic: Business Wire)

(Graphic: Business Wire)

Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Northwest Biotherapeutics.

NWBT Highlights Cost Effectiveness Of DCVax® In View Of Recent Immunotherapy Pricing Concerns

NWBT Highlights Cost Effectiveness Of DCVax® In View Of Recent Immunotherapy Pricing Concerns

Northwest Biotherapeutics (OTCBB: NWBO) reminded markets, in response to recent investor concerns about Dendreon’s Provenge immune therapy, that NWBT’s DCVax® immune therapies for a broad range of cancers...

NWBT Announces Further Expansion Of Clinical Sites In Ongoing Brain Cancer Trial

NWBT Announces Further Expansion Of Clinical Sites In Ongoing Brain Cancer Trial

Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.

Family Foundation Of Business Leader Invests $4.55 Million In Northwest Biotherapeutics For Promising Clinical Trials In The US And Europe

Family Foundation Of Business Leader Invests $4.55 Million In Northwest Biotherapeutics For Promising Clinical Trials In The US And Europe

Northwest Biotherapeutics (OTCBB:NWBO) ("NWBT") announced today a $4.

Northwest Biotherapeutics Announces Change And Expansion Of Management Team

Northwest Biotherapeutics Announces Change And Expansion Of Management Team

Northwest Biotherapeutics (OTCBB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives.

Northwest Biotherapeutics Announces Series Of Financing Arrangements

Northwest Biotherapeutics Announces Series Of Financing Arrangements

Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further ...

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

Northwest Biotherapeutics (OTCBB:NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.

Northwest Biotherapeutics And The Fraunhofer Institute For Cell Therapy And Immunology Are Partnering For Clinical Trials And Compassionate Use Cases In Europe

Northwest Biotherapeutics And The Fraunhofer Institute For Cell Therapy And Immunology Are Partnering For Clinical Trials And Compassionate Use Cases In Europe

Northwest Biotherapeutics (OTCBB:NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The mailbag returns with questions about Northwest Biotherapeutics, Flamel and, of course, Dendreon.